COL18A1 and neoplasm: Our results are in agreement with those of Calvo et al (2002) who showed, in the C3(1)/SV40 transgenic mouse model, that P125A-endostatin treatment suppressed mRNA and protein levels of VEGF, Female C3(1)/SV40 mice treated with P125A-endostatin for a 3-week period showed significant delay in tumour development, reduced tumour burden and increased survival (Calvo et al, 2002).